# EXODOTS for diagnostic evaluation and monitoring of Alzheimer's disease

> **NIH NIH R43** · WELLSIM BIOMEDICAL TECHNOLOGIES, INC. · 2022 · $291,692

## Abstract

PROJECT SUMMARY / ABSTRACT
Alzheimer's disease (AD) is the most widespread neurodegenerative disorder. Despite the severity of the disease,
early diagnosis of AD is still challenging due to the low accuracy or high cost of neuropsychological tests and
neuroimaging. Development of an accurate and cost-effective technology for non-invasive screening and
monitoring of AD before irreversible brain damage or mental decline is critical. WellSIM proposes to develop and
validate a highly sensitive immunofluorescence assay, termed EXODOTS, for detection and quantification of AD
core biomarkers from circulating extracellular vesicles (EV) with high accuracy, high speed, and low cost. This
blood-based assay will facilitate minimally invasive assessment of AD patients in primary care settings and
continuous monitoring of disease progression.

## Key facts

- **NIH application ID:** 10600890
- **Project number:** 1R43AG080878-01
- **Recipient organization:** WELLSIM BIOMEDICAL TECHNOLOGIES, INC.
- **Principal Investigator:** Yuchao Chen
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $291,692
- **Award type:** 1
- **Project period:** 2022-09-30 → 2024-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10600890

## Citation

> US National Institutes of Health, RePORTER application 10600890, EXODOTS for diagnostic evaluation and monitoring of Alzheimer's disease (1R43AG080878-01). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10600890. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*